Opiant Pharmaceuticals Stock News

SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, will participate in a fireside chat at the 32 nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - March 17. Management will also host investor 1x1 meetings.

SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug ov

Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) announced topline results from a multi-dose pharmacokinetic (PK) study for OPNT003, nasal nalmefene, for opioid overdose. The crossover design study was conducted in 23 healthy subjects comparing the PK profile, safety, and tolerability of OPNT003 when given as a single 3mg … Full story available on Benzinga.com

Opiant Pharmaceuticals (OPNT) briefly gained 1.5% after a report that the company is speculated to be a takeover target.A large rival is said to be circling the pharmaceutical…

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmaceuticals Inc's (NASDAQ: OPNT) OPNT003, nasal nalme

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD).  The trial will determine whether OPNT002 reduc

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Oppenheimer issued their FY2021 earnings estimates for shares of Opiant Pharmaceuticals in a research report issued on Wednesday, December 8th. Oppenheimer analyst L. Gershell expects that the technology company will earn $0.26 per share for the year. Oppenheimer has a Outperform rating and a $42.00 price target on the stock. []

Wells Fargo & Company MN boosted its holdings in shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) by 0.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 251,007 shares of the technology companys stock after purchasing an additional 925 shares during the []

Investment analysts at Oppenheimer initiated coverage on shares of Opiant Pharmaceuticals (NASDAQ:OPNT) in a research report issued on Wednesday, The Fly reports. The brokerage set an outperform rating on the technology companys stock. NASDAQ OPNT traded up $2.26 on Wednesday, hitting $32.20. 260 shares of the company were exchanged, compared to its average volume of []

Overdose crisis that killed over 100,000 Americans in one year is ''all about fentanyl'', says Roger Crystal of Opiant Pharmaceuticals

Analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will announce sales of $14.38 million for the current quarter, according to Zacks. Two analysts have made estimates for Opiant Pharmaceuticals earnings, with estimates ranging from $14.15 million to $14.60 million. Opiant Pharmaceuticals posted sales of $9.92 million during the same quarter last year, which would indicate a []

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 24,400 shares, a growth of 25.8% from the October 31st total of 19,400 shares. Based on an average daily volume of 55,300 shares, the short-interest ratio is []

Northern Trust Corp grew its stake in shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) by 17.6% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 37,958 shares of the technology companys stock after acquiring an additional 5,668 shares during the quarter. Northern Trust Corp owned about [] The post Northern Trust Corp Buys 5,668 Shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) appeared first on ETF Daily News .

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) saw a large decrease in short interest in October. As of October 29th, there was short interest totalling 19,400 shares, a decrease of 41.7% from the October 14th total of 33,300 shares. Based on an average trading volume of 55,400 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.5% of []

Analysts expect that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will announce earnings of $0.19 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Opiant Pharmaceuticals earnings. The lowest EPS estimate is ($0.27) and the highest is $0.64. Opiant Pharmaceuticals reported earnings per share of ($0.16) during the same quarter last year, []